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Abstract
Background Sunitinib is a multi-targeted tyrosine kinase
inhibitor used in the treatment of advanced renal cell car-
cinoma (RCC) and imatinib-resistant/intolerant gastroin-
testinal stromal tumors (GIST).
Methods A meta-analysis of 10 prospective clinical studies
in advanced RCC and GIST was performed to support the
development of pharmacokinetic (PK) and PK/pharmaco-
dynamic (PD) models that account for the effects of
important covariates. These models were used to make
predictions with respect to the PK, safety, and efficacy of
sunitinib when administered on the traditional 4-weeks-on/
2-weeks-off schedule (Schedule 4/2) versus an alternative
schedule of 2 weeks on/1 week off (Schedule 2/1).
Results The covariates found to have a significant effect on
one or more of the PK or PD parameter studies included,
age, sex, body weight, race, baseline Eastern Cooperative
Oncology Group performance status, tumor type, and
dosing schedule. The models predicted that, in both RCC
and GIST patients, Schedule 2/1 would have comparable
efficacy to Schedule 4/2, despite some differences in PK
profiles. The models also predicted that, in both indica-
tions, sunitinib-related thrombocytopenia would be less
severe when sunitinib was administered on Schedule 2/1
dosing compared with Schedule 4/2.
Conclusion These findings support the use of sunitinib on
Schedule 2/1 as a potential alternative to Schedule 4/2
because it allows for the management of toxicity without
loss of efficacy.
Key Points
This analysis compared the efficacy and safety of
sunitinib administered on Schedule 2/1 dosing versus
Schedule 4/2 (i.e. weeks on/weeks off) using
mechanism-based and semi-mechanistic
pharmacokinetic/pharmacodynamic models.
The models predicted that efficacy with sunitinib
administered on Schedule 2/1 would be comparable
to Schedule 4/2, but thrombocytopenia would be less
severe on Schedule 2/1.
Schedule 2/1 may be a preferred regimen for
sunitinib in patients with advanced RCC or
gastrointestinal stromal tumors as it is predicted to be
as efficacious with better tolerability compared with
Schedule 4/2.
1 Introduction
Sunitinib is an orally administered, multi-targeted tyrosine
kinase inhibitor with potent antiangiogenic and antitumor
activity [1]. The advent of sunitinib and other antiangiogenic
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therapies has revolutionized the therapeutic landscape for
patients with advanced renal cell carcinoma (RCC) or
imatinib-resistant/intolerant gastrointestinal stromal tumors
(GIST), considerably improving outcomes compared with
previous management paradigms [2–4]. For any therapeu-
tic agent, a key challenge is to achieve efficacy while
minimizing treatment-related adverse events (AEs), so that
both therapy compliance and on-treatment time are maxi-
mized [5]. It is recommended that sunitinib (50 mg once
daily) be administered for 4 consecutive weeks followed by
2-weeks-off treatment (‘Schedule 4/2’) in RCC and GIST
patients, as was employed in the pivotal phase III trials in
these indications [2, 6]. However, due to drug toxicity,
28–38 and 11–32 % of sunitinib-treated patients in these
trials experienced dose interruptions and reductions,
respectively [2, 6], instigating efforts to optimize the dos-
ing schedule to improve tolerance. In an open-label, phase
II trial of cytokine-refractory metastatic RCC patients,
continuous daily dosing (CDD) with 37.5 mg displayed a
manageable safety profile [7]. However, no difference in
AE incidence between this regimen and Schedule 4/2 was
observed in a randomized, phase II trial that directly
compared these regimens as first-line therapy in patients
with advanced RCC. Furthermore, time to tumor progres-
sion (TTP) was numerically longer on Schedule 4/2 than
CDD [8]. In patients with imatinib-resistant/intolerant
GIST, an open-label, phase II trial showed CDD with
37.5 mg to be active, with an acceptable safety profile [9].
These results were broadly similar to those of the phase III
trial of sunitinib in GIST [2, 9].
A previous pharmacokinetic/pharmacodynamic (PK/
PD) meta-analysis of data from studies in patients with
solid tumors, including RCC and GIST, predicted that
increased sunitinib exposure was associated with improved
efficacy but increased AE risk [10]. With the aim of pre-
serving sunitinib efficacy while minimizing treatment-re-
lated toxicity, the utility of a 2-weeks-on/1-week-off
schedule (‘Schedule 2/1’) in RCC has been investigated in
clinical practice. Retrospective reports suggest that with
Schedule 2/1 dosing, the efficacy of sunitinib was pre-
served and the toxicity profile was more manageable than
Schedule 4/2 [11–14]. Data comparing the efficacy and
safety of Schedule 4/2 with Schedule 2/1 in GIST patients
are currently lacking [15].
It has been previously shown that the efficacy and tox-
icity of sunitinib could be predicted by PK/PD modeling
[10, 16]. Our objective was to develop PK and PK/PD
models that took into account the effects of important
covariates by pooling data from 10 prospective clinical
studies in adult patients with RCC or GIST. The models
were used to make predictions with respect to the PK,
safety, and efficacy of sunitinib in these patients on
Schedule 2/1 compared with Schedule 4/2.
2 Methods
2.1 Study Designs
This retrospective PK/PD meta-analysis pooled data from
10 phase I–III clinical studies. Six studies were conducted
in patients with advanced RCC (N = 578 total evaluable
patients, of whom 395 patients were included in the PK
analysis) [7, 8, 17–20]. Sunitinib was administered orally
according to one of two schedules: Schedule 4/2 at 50 mg
or CDD 37.5 mg. Four studies were conducted in patients
with advanced GIST exhibiting resistance or intolerance to
imatinib (N = 365 total evaluable patients, of whom 252
patients were included in the PK analysis) [9, 21–23].
Sunitinib was administered orally according to one of the
following schedules: Schedule 4/2, doses between 25 and
75 mg; Schedule 2/2, doses between 25 and 75 mg;
Schedule 2/1 at 50 mg; or CDD 37.5 mg. All studies were
approved by Institutional Review Boards or independent
Ethics Committees, and all patients provided written
informed consent.
2.2 Study Assessments
Blood samples for PK assessments were taken at pre-
specified visits per each study protocol (trough PK: all
studies; full profile PK: two studies). Plasma samples were
analyzed for quantification of the concentrations of suni-
tinib and its active metabolite SU12662 using a validated
liquid chromatography–tandem mass spectrometry assay
(BASi, West Lafayette, IN, USA), as previously described
[31]. Tumor measurements were recorded regularly (once
every cycle or every other cycle following each study
protocol requirements) and responses defined using
Response Evaluation Criteria in Solid Tumors (RECIST),
version 1.0 [24]. Safety and tolerability were assessed
regularly and AEs were graded according to National
Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0.
2.3 Pharmacokinetic (PK) Models
PK data were pooled and randomly split, at study and
subject level, into the working dataset used to develop the
PK models (70 %) and the external validation dataset
(30 %). Plasma concentration–time data for sunitinib and
SU12662 were each separately analyzed using nonlinear
mixed-effects modeling (NONMEM, version 7.1.2) [25] to
estimate population PK parameters (mean and intersubject
variability) and identify potential covariates to explain
intersubject variability in the parameters. Analyses were
performed using the first-order conditional estimation
method with interaction (FOCEI) approximation method in
1252 R. Khosravan et al.
NONMEM. Methods used to generate and validate the PK
models are described in the Methods section in the elec-
tronic supplementary material (ESM).
2.4 PK/Pharmacodynamic (PD) Model
Sequential PK/PD modeling was performed using the
FOCEI approximation method. The efficacy endpoint
modeled was target tumor sum of the largest diameter
(SLD). Modeled safety endpoints were related to the most
common sunitinib AEs and included absolute neutrophil
count (ANC), platelet count (PC), lymphocyte count (LC),
diastolic blood pressure (DBP), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and left ven-
tricular ejection fraction (LVEF) [2, 6]. The type of PK/PD
modeling performed to distinguish between the effects on
safety of different dosing schedules (while total dose over a
42-day cycle remained unchanged) required the presence
of continuous quantitative safety measures/endpoints.
Therefore, the PK/PD modeling approach could not be
applied to categorical safety endpoints (e.g. fatigue, hand–
foot syndrome, nausea, vomiting, diarrhea, or others). Only
PK model-predicted sunitinib concentrations were used to
build the PK/PD models (see the Methods section in the
ESM regarding the development of the PK/PD models).
2.5 Patient Population Simulation
Using the final population PK and PK/PD models, trial
simulations were performed to provide predictions with
respect to the PK of sunitinib and SU12662, and the safety
and efficacy of sunitinib 50 mg on Schedule 2/1 (n = 100)
compared with Schedule 4/2 (n = 100) in patients with
advanced RCC or GIST. For the purpose of this simulation
exercise, a full cycle was defined as a 42-day period. For
Schedule 4/2, a full cycle comprised 28 days of daily
dosing followed by 14 days off treatment. For Schedule
2/1, a full cycle comprised two periods of 14 days of daily
dosing followed by 7 days off treatment. A total of 20 trial
simulations were run in which RCC or GIST patients were
assigned demographics consistent with those from the
pooled dataset for the RCC or GIST patient population
from the sunitinib trials dataset included in the modeling
portion. One set of trial simulations was run to predict the
values of target tumor SLD during cycle 6 for each dosing
schedule, and the values of the safety endpoints during
cycle 3. Another set was run to predict the incidence rates
of different grades of AEs during the first three cycles and
the progression-free survival (PFS)/TTP and objective
response rate (ORR) values based on the predicted SLD for
each dosing schedule (see the Methods section in the
ESM).
3 Results
3.1 Baseline Patient Characteristics and Covariates
Data from 647 patients with advanced RCC or GIST
contributed to the analysis. Baseline patient characteristics
of the working dataset, summarized in Table 1, were
generally representative of the original trial populations.
The patient characteristics of the validation dataset
resembled those of the working dataset. In all, 395
(61.1 %) and 252 (38.9 %) RCC and GIST patients,
respectively, were included in the analysis. The PK anal-
ysis included patients from all dosing schedules (%
patients), including Schedule 4/2 (63.4 %), a 2-weeks-on/
2-weeks-off schedule (Schedule 2/2; 3.1 %), Schedule 2/1
(0.8 %), and CDD (32.8 %). All patients receiving
Schedules 2/2 and 2/1 had GIST. Of the PK patient pop-
ulation, only a subset of patients who had the specific
efficacy or safety endpoints from all dosing regimens were
included in the PK/PD analysis.
In the analyses described below, the following covari-
ates were found to have a significant effect on one or more
of the PK or PD parameters studied: age (AGE), sex (SEX),
body weight (BWT), race (RAC), baseline Eastern Coop-
erative Oncology Group performance status (ECOG PS
[BEC]), tumor type (TUMR), and dosing schedule (SCH).
3.2 PK Models
A two-compartment model with first-order rates of
absorption (Ka) and elimination (Ke) was developed and
validated for sunitinib and its primary metabolite SU12662.
Absorption lag time (tlag) was included in the sunitinib PK
model, but not for SU12662. PK parameter estimates from
the final and bootstrap models for sunitinib and its
metabolite are summarized in Table 2.
The PK parameters with significant covariate effects in
the final model for sunitinib, plus the significant covariates
themselves, are shown in Eqs. 1 and 2:
CL=F ¼ 34:1 10:00702 AGE58ð Þð Þ
 10:152 RACð Þ  10:193 SEXð Þ
 1þ 0:293 TUMRð Þ; ð1Þ
Vc=F ¼ 2700 BWT=77:4ð Þ0:281 10:213 SEXð Þ
 1þ 0:42 TUMRð Þ: ð2Þ
Thus, sunitinib apparent clearance (CL/F) decreased
with age (-0.702 % per year), Asian ethnicity (-15.2 %),
and in females (-19.3 %), and increased in patients with
GIST (?29.3 %). Sunitinib central compartment volume
(Vc/F) increased in patients with GIST (?42 %) and as
BWT increased (e.g. ?20.4 % for 150 vs. 77.4 kg), and
decreased in females (-21.3 %).
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PK parameters with significant covariate effects in the
final model for SU12662 were as shown in Eqs. 3 and 4:
CL=F ¼ 17:5 10:00743 AGE58ð Þð Þ
 10:205 RACEð Þ  10:354 SEXð Þ
 1þ 0:324 TUMRð Þ; ð3Þ
Vc=F ¼ 2120 1þ 0:00892 BWT77:3ð Þð Þ
 10:272SEXð Þ 1þ 0:635TUMRð Þ: ð4Þ
Thus, the same covariates influenced SU12662
CL/F and Vc/F, as in the model for sunitinib. SU12662
CL/F decreased with age (-0.743 % per year), Asian
Table 1 Baseline patient
characteristics (N = 647)a
n Mean ± SD Median Range
Continuous variables
Age, years 647 57.6 ± 11.2 58 23–84
Body weight, kg 641 77.4 ± 19.3 77.2 39.1–154
Height, cm 631 169 ± 10.4 170 137–201
Body surface, m2 629 1.87 ± 0.255 1.87 1.24–2.6
AST, U/L 637 24.8 ± 13.1 22 3–114
ALT, U/L 637 25.6 ± 17.5 22 4–168
CrCl, mL/min 631 81.8 ± 29.9 78.1 24.2–241
Diastolic BP, mmHg 644 74.8 ± 10.6 75 20–100
ANC, 109/L 591 5.06 ± 2.5 4.51 1.15–21.8
Platelet count, 109/L 635 316 ± 137 280 102–1070
Lymphocyte count, 109/L 591 1.62 ± 0.859 1.47 0.3–12.7
Hemoglobin, g/dL 628 50.6 ± 53 14.1 5.1–163
LVEF, % 424 64.4 ± 7.47 65 45–85























ALT alanine aminotransferase, ANC absolute neutrophil count, AST aspartate aminotransferase, BP blood
pressure, CDD continuous daily dosing, CrCl creatinine clearance, ECOG PS Eastern Cooperative
Oncology Group performance status, GIST gastrointestinal stromal tumor, LVEF left ventricular ejection
fraction, PK pharmacokinetic, RCC renal cell carcinoma, SD standard deviation
a Based on the working PK dataset for patients with at least one measurable PK sample
b Weeks on/weeks off treatment or CCD
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ethnicity (-20.5 %), and in females (-35.4 %), and
increased in patients with GIST (?32.4 %). SU012662
Vc/F increased in patients with GIST (?63.5 %) and as
BWT increased (?0.892 % per kg), and decreased in
females (-27.2 %).
To test the goodness-of-fit of the final PK models for
sunitinib and its metabolite, plots were generated, includ-
ing individual predicted versus observed concentrations
(Fig. 1), population predicted versus observed concentra-
tions (Fig. 2), and weighted residuals versus time or pre-
dictions (Figs. S1 and S2 of the ESM, respectively). The
simulated concentrations agreed well with the observed
concentrations using visual predictive check (VPC) tech-
niques for both the working and validation datasets
(Figs. 3, 4, respectively). In addition, mean and 95 %
confidence interval (CI) values generated by the model
were similar to the those generated by bootstrapping
(Table 2).
3.3 Sequential PK/PD Models
Sequential PK/PD models for efficacy and safety end-
points were built using final PK model-predicted suni-
tinib concentrations. SU12662 data were not included in
this process as tests showed inclusion of predicted
metabolite concentrations did not improve the model
objective function value and was associated with longer
run times. Results for the PK/PD models are summarized
in Table 3.
3.3.1 Efficacy Endpoint: Target Tumors’ Sum of Longest
Diameters
A sequential indirect response (IDR) PK/PD model
(Fig. 5a), with a tolerance function (Ktol) on the output
elimination rate (Kout) and a maximum drug effect (Emax)
effect function on the input rate constant (Kin), was used as
Table 2 Summary of PK parameters for sunitinib and its active metabolite SU12662 in the final population PK models
Parameter Sunitinib SU12662
Final model results Bootstrap model results Final model results Bootstrap model results
Population mean estimates (95 % CI)a
CL/F, L/h 34.1 (32.7–35.5) 34.9 (33.0–35.8) 17.5 (16.5–18.5) 17.3 (16.5–18.3)
Vc/F, L 2700 (2543–2857) 2720 (2320–2800) 2120 (1925–2315) 2130 (1860–2420)
Ka, h
-1 0.126 (0.106–0.146) 0.116 (0.134–0.201) 0.102 (0.0714–0.133) 0.108 (0.0733–0.154)
tlag, h 0.527 (0.508–0.546) 0.529 (0.507–0.954) NA NA
Vp/F, L 774 (713–835) 806 (523–1210) 751 (708–794) 762 (535–1170)













-0.152 (-0.209 to -0.0954) -0.158 (-0.216 to -0.101) -0.205 (-0.278 to -0.132) -0.200 (-0.273 to -0.118)
SEX on CL/F -0.193 (-0.232 to -0.154) -0.202 (-0.252 to -0.151) -0.354 (-0.402 to -0.306) -0.348 (-0.397 to -0.295)
TUMR on
CL/F
0.293 (0.230–0.356) 0.275 (0.200–0.360) 0.324 (0.223–0.425) 0.326 (0.230–0.429)
BWT on Vc/F 0.281 (0.128–0.434) 0.281 (0.159–0.529) 0.00892 (0.00614–0.0117) 0.00752 (0.00351–0.0117)
SEX on Vc/F -0.213 (-0.275 to -0.151) -0.216 (-0.289 to -0.114) -0.272 (-0.376 to -0.168) -0.322 (-0.431 to -0.199)
TUMR on
Vc/F
0.420 (0.316–0.524) 0.427 (0.311–0.637) 0.635 (0.417–0.853) 0.652 (0.435–0.929)
Residual variability %CV (95 % CI)a
41.7 (41.4–42.0) 41.9 (39.0–44.0) 36.9 (36.5–37.3) 36.9 (34.8–38.7)
Interpatient variability %CV (95 % CI)a
CL/F 24.6 (22.8–26.3) 24.1 (21.1–27.0) 36.3 (33.9–38.6) 36.1 (32.8–39.7)
Vc/F 23.0 (20.4–25.4) 21.9 (15.8–29.4) 47.3 (43.4–50.9) 49.5 (40.0–60.0)
Ka 166 (146–183) 172 (152–202) 126 (85.6–156) 130 (100–155)
BWT baseline weight, CI confidence interval, CL/F apparent clearance, CV coefficient of variation, Ka absorption rate constant, NA not
applicable, PK = pharmacokinetic, Q/F intercompartmental clearance, RAC race, SE standard error, tlag lag time, SEX sex, TUMR tumor, Vc/F
central compartment apparent volume of distribution, Vp/F peripheral compartment apparent volume of distribution
a 95 % CI was estimated as (mean - 1.96 9 SE - mean ? 1.96 9 SE)
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Fig. 1 Goodness-of-fit diagnostic plots for (a) plasma concentrations
of sunitinib (final PK model); (b) plasma concentrations of the
sunitinib active metabolite SU12662 (final PK model); (c) efficacy
endpoint sum of longest diameter in target lesions (final PK/PD
model); and (d–j) selected safety endpoints (final PK/PD model).
Solid red lines in DV versus IPRED plots are lines of unity. Solid blue
lines are the PRED regression lines. PD pharmacodynamic, PK
pharmacokinetic, DV observed, IPRED individual predicted, PRED
predicted
























































































































Fig. 2 Goodness-of-fit diagnostic plots, observed vs. population
predicted for (a) plasma concentrations of sunitinib (final PK model);
(b) plasma concentrations of the sunitinib active metabolite SU12662
(final PK model); (c) efficacy endpoint sum of longest diameter in
target lesions (final PK/PD model); and (d–j) selected safety
endpoints (final PK/PD model). Solid red lines in DV versus
population PRED plots are lines of unity. Solid blue lines are the
PRED regression lines. PD pharmacodynamic, PK pharmacokinetic,
DV observed, PRED predicted
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Fig. 3 Prediction and variance-corrected visual predictive check plot
(final model) for (a) plasma concentrations of sunitinib; (b) plasma
concentrations of the sunitinib active metabolite SU12662; (c) efficacy
endpoint sum of longest diameter in target lesions; and (d–j) selected
safety endpoints. ALT alanine aminotransferase, AST aspartate
aminotransferase, LVEF left ventricular ejection fraction, DBP
diastolic blood pressure, ANC absolute neutrophil count
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Fig. 4 Prediction and variance-corrected visual predictive check plot
(validation data set) for (a) plasma concentrations of sunitinib;
(b) plasma concentrations of the sunitinib active metabolite SU12662;
(c) efficacy endpoint sum of longest diameter in target lesions; and
(d–j) selected safety endpoints. ALT alanine aminotransferase, AST
aspartate aminotransferase, LVEF left ventricular ejection fraction,
DBP diastolic blood pressure, ANC absolute neutrophil count
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the model for SLD. Mean SLD at baseline was 14.3 cm.
Mean Kout was 0.000267 h
-1 and Emax was fixed to 1.
Mean concentration producing 50 % of the maximum
effect (EC50) was 30.5 ng/mL, and Ktol was 0.0000141 h
-1
(i.e. translating into a 5 and 10 % decrease for Kout 9
e-Ktol 9 time value in approximately 5 and 10 months,
respectively).
PK/PD parameters with significant covariates effects in
the final model were as shown in Eqs. 5, 6, and 7:
Baseline SLD ¼ 14:3 1þ 0:574 BECð Þ
 10:348 RACð Þ
 10:43 SCHð Þ ð5Þ
Kout ¼ 0:000267 1þ 1:01 SCHð Þ ð6Þ
EC50 ¼ 30:5 1þ 2:43 SCHð Þ  1þ 4:82 TUMRð Þ:
ð7Þ
Baseline SLD was higher with ECOG PS C1
(?57.4 %), and lower with Asian ethnicity (-34.8 %)
and Schedule CDD (-43 %). Kout was higher for Schedule
CDD (?101 %). In addition, EC50 was higher for Schedule
CDD (?243 %) and for patients with GIST (?482 %). For
the SLD models, goodness-of-fit diagnostic plots were
generated, including individual predicted versus observed
data (Fig. 1), population predicted versus observed data
(Fig. 2), and weighted residuals versus time or predictions
(Figs. S1and S2 of the ESM, respectively). Simulated
predictions agreed well with observed data using VPC
techniques for both the working and validation datasets
(Figs. 3, 4, respectively). In addition, mean and 95 % CI
values generated by the models were consistent with those
generated by bootstrapping (Table 3).
3.3.2 Safety Endpoints
ALT, AST, LVEF, and DBP: For the safety endpoints ALT,
AST, LVEF, and DBP, a sequential PK/PD IDR model
with first-order rate constant (KPD) on Kout (Fig. 5a)
appeared to be the most parsimonious model with suc-
cessful minimization, which met the diagnostic criteria.
This model was therefore selected for these endpoints.
Mean (95 %CI) ALT at baselinewas 21.2 (20.5–21.9) U/
L. For the ALT model, mean (95 % CI) Kout and KPD were
0.00916 (0.00667–0.0116) h-1 and 0.00401 (0.00362–
0.00440) mL/ng, respectively. BWT had a significant effect
on baseline ALT and was modeled as per Eq. 8:
Baseline ALT ¼ 21:2 BWT=77:3ð Þ0:376: ð8Þ
Mean (95 % CI) AST at baseline was 21.5 (20.7–22.3)
U/L, and, in the AST model, mean (95 % CI) Kout and KPD
were 0.0142 (0.0114–0.0170) h-1 and 0.00572 (0.00536–
0.00608) mL/ng, respectively. Baseline AST was higher in
patients with GIST (?11.7 %), as shown in Eq. 9:
Baseline AST ¼ 21:5 1þ 0:117 TUMRð Þ: ð9Þ
KPD for AST was higher in patients with baseline ECOG
PS C1 (BEC) (?20 %), and lower in patients with GIST
(-17.5 %), as shown in Eq. 10:
KPD ¼ 0:00572 1þ 0:2 BECð Þ
 10:175 TUMRð Þ: ð10Þ
Mean (95 % CI) LVEF at baseline was 62.2 % (61.2–
63.2 %). For the LVEF model, mean (95 % CI) Kout and
KPD were 0.000656 (0.000409–0.000903) h
-1 and 0.00131
(0.000965–0.00165) mL/ng, respectively. Baseline LVEF
was higher in Asian patients (?8.91 %) and in females
(?4.21 %), as shown in Eq. 11:
Baseline LVEF ¼ 62:2 1þ 0:0891 RACð Þ
 1þ 0:0421 SEXð Þ: ð11Þ
Mean (95 % CI) DBP at baseline was 74.6 (74.0–75.2)
mmHg. For the DBP model, mean (95 % CI) Kout and KPD
were 0.0288 (0.0149–0.0427) h-1 and 0.00184 (0.00169–
0.00199) mL/ng, respectively. BWT significantly
influenced baseline DBP, an effect that was modeled as
per Eq. 12:
Baseline DBP ¼ 74:6 BWT=77:3ð Þ0:0691: ð12Þ
For the ALT, AST, LVEF, and DBP models, goodness-
of-fit diagnostic plots were generated, including individual
predicted versus observed data (Fig. 1), population
predicted versus observed data (Fig. 2), and weighted
residuals versus time or predictions (Figs. S1 and S2 of the
ESM, respectively). Simulated predictions agreed well
with observed data using VPC techniques for both the
working and validation datasets (Figs. 3, 4, respectively).
In addition, mean and 95 % CI values generated by the
models were consistent with those generated by
bootstrapping (Table 3).
ANC, LC, and PC A sequential transit compartment in
series with feedback loop (TCSFL) PK/PD model (Fig. 5b)
with an Emax model effect on the proliferation rate constant
of the endpoint in the proliferation compartment (Kprol) in
the stem cell compartment was used as the initial model for
ANC, LC, and PC. Subsequently, a reduced model such as
TCSFL with a KPD-type effect or simpler models were also
examined. For ANC and PC, the initial model appeared to
be the most parsimonious model and was thus selected. For
LC, the reduced TCSFL model with a KPD-type effect
appeared to be the most parsimonious and was thus
selected.
Mean (95 % CI) ANC at baseline was 4.61 (4.42–
4.80) 9 109/L. For the ANC model, mean (95 % CI)
transit time from the proliferation compartment to the
circulation compartment (MTT), Emax, EC50, power func-
tion for the rebound of feedback loop (POW), and power
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function for the sigmoidal Emax model (LAM) values were
182 (177–187) h, 0.126 (0.118–0.134), 11.1 (9.42–
12.8) ng/mL, 0.152 (0.145–0.159), and 1.72 (1.41–2.03),
respectively. ANC at baseline was lower in Asian patients
(-29.7 %) and higher in patients with ECOG PS C1
(?13.4 %), as shown in Eq. 13:
Baseline ANC ¼ 4:61 10:297 RACð Þ
 1þ 0:134 BECð Þ ð13Þ
Mean (95 % CI) LC at baseline was 1.51 (1.44–1.58)
109/L. For the LC model, mean (95 % CI) MTT, KPD, and
POW were 243 (226–260) h, 0.000687 (0.000603–
0.000771) mL/ng, and 0.200 (0.183–0.217), respectively.
LC at baseline was lower in patients with ECOG PS C1 (-
12.1 %), as shown in Eq. 14:
Baseline LC ¼ 1:51 10:121 BECð Þ: ð14Þ
MTT for LC was lower in Asian patients (-39.8 %)
(Eq. 15):
MTT ¼ 243 10:398 RACð Þ: ð15Þ
KPD for LC was lower in patients on the CDD schedule
(-41.7 %) (Eq. 16):
KPD ¼ 0:000687 10:417 SCHð Þ: ð16Þ
Mean (95 % CI) PC at baseline was 297 (287–307) 109/L.
For the PC model, mean (95 % CI) MTT, Emax, EC50,
POW, and LAM were 88.4 (84.2–92.6) h, 0.154 (0.135–
0.173), 65.0 (60.0–70.0) ng/mL, 0.0895 (0.0861–0.0929),
and 3.09 (2.82–3.36), respectively. PC at baseline was
lower with increasing BWT (-0.327 % per kg) and in
Asian patients (-25.5 %) (Eq. 17):
Baseline PC ¼ 297 10:00327 BWT77:3ð Þð Þ
 10:255 RACð Þ: ð17Þ
MTT was higher in patients with ECOG PS C1
(?11.8 %) and lower in Asian patients (-19.5 %)
(Eq. 18):
MTT ¼ 88:4 1þ 0:118 BECð Þ  10:195 RACð Þ:
ð18Þ
Emax was lower with increasing BWT (-0.742 % per
kg) (Eq. 19):
Emax ¼ 0:154 10:00742 BWT77:3ð Þð Þ: ð19Þ
EC50 was lower in patients with GIST (-10.8 %)
(Eq. 20):
EC50 ¼ 65:0 10:108 TUMRð Þ: ð20Þ
For the ANC, LC, and PC models, goodness-of-fit
diagnostic plots were generated, including individual
predicted versus observed data (Fig. 1), population
predicted versus observed data (Fig. 2), and weighted
residuals versus time or predictions (Figs. S1 and S2 of the
ESM, respectively). Simulated predictions agreed with
observed data using VPC techniques for both the working
and validation datasets (Figs. 3, 4). In addition, mean and
95 % CI values from the model were similar to those
generated by bootstrapping (Table 3).
3.4 Patient Population Simulation
3.4.1 PK
Trial simulations on the PK model for sunitinib and its
metabolite were run to predict their concentrations in
patients with advanced RCC when sunitinib was adminis-
tered on Schedule 2/1 compared with Schedule 4/2
(Fig. 6). In these patients, mean (95 % CI) trough sunitinib
concentrations during cycle 3 on Schedule 4/2 and
Schedule 2/1 were 42.6 (38.6–45.8) ng/mL and 42.4
(40.4–44.1) ng/mL, respectively (Fig. 6a). Mean (95 % CI)
trough SU12662 concentrations in RCC patients during
cycle 3 on Schedule 4/2 and Schedule 2/1 were 19.7
(16.9–21.6) ng/mL and 19.5 (18.2–20.7) ng/mL, respec-
tively (Fig. 6c). The duration of time at maximum and
minimum drug concentrations during the respective on-
treatment and off-treatment periods within a 42-day cycle
were shorter for Schedule 2/1 compared with Schedule 4/2
for both sunitinib and its metabolite (Fig. 6a, c). During the
last day of the on-drug period, mean (95 % CI) sunitinib
concentration on Schedule 4/2 and Schedule 2/1 was 67.3
(61.3–71.5) ng/mL and 65.5 (62–67.2) ng/mL, respectively
(Fig. 6b). Mean (95 % CI) SU12662 concentration on this
day was 29.5 (25.6–31.9) ng/mL and 27.7 (25.7–28.9) ng/
mL, respectively (Fig. 6d). Similar results were obtained
for simulations with GIST patients (see the ‘‘Results’’ and
Fig. S3 of the ESM).
3.4.2 Efficacy Endpoint: Target Tumor Sum of the Largest
Diameter
Based on the final PK/PD efficacy model, trial simulations
were performed to assess whether the predicted differences
between the PK profiles of the two schedules had an impact
on the efficacy of sunitinib in patients with advanced RCC.
The endpoint used in this assessment was target tumor SLD
(Fig. 7a). Based on the simulation results, median (95 %
CI) SLD values at the end of cycle 6 for Schedule 4/2 and
Schedule 2/1 were 8.6 (7.8–9.3) cm and 8.2 (7.4–8.8) cm,
respectively. Furthermore, the simulated SLD values were
then used to estimate PFS and ORR. The predicted median
(95 % CI) PFS on Schedule 4/2 and Schedule 2/1 was 47.2
(30.9–54.6) weeks and 54.3 (35.1–59.9) weeks, respec-
tively, while the predicted median (95 % CI) ORR on
Schedule 4/2 and Schedule 2/1 was 27.0 % (20.5–34.5) and
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Table 3 Summary of population parameter estimates in the final PK/PD models
Model results Bootstrap results
Estimate (95 % CI)a Intersubject
variability
(95 % CI)a




Tumor sum of longest diameters
BASE, cm 14.3 (12.9–15.7) 91.7 (86.7–96.4) 14.6 (12.8–16.5) 91.5 (85.6–97.7)
Kout, h
-1 0.000267 (0.000224–0.00031) 72.2 (61.2–81.7) 0.000270 (0.000190–0.000330) 81.6 (66.3–95.9)
Emax 1 (FIXED) – 1 (FIXED) –
EC50, ng/mL 30.5 (19.3–41.7) 182 (165–197) 29.6 (17.0–44.7) 186 (158–219)
Ktol, h
-1 0.0000141 (0.00000881–0.0000194) 84.9 (51.3–108) 0.0000144 (0.00000685–0.0000219) 101 (64.9–157)
BEC on BASE 0.574 (0.321–0.827) – 0.546 (0.352–0.822) –
RAC on BASE -0.348 (-0.496 to -0.200) – -0.361 (-0.467 to -0.241) –
SCH on BASE -0.430 (-0.531 to -0.329) – -0.430 (-0.505 to -0.356) –
SCH on Kout 1.01 (0.557–1.46) – 1.26 (0.383–2.45) –
SCH on EC50 2.43 (0.901–3.96) – 2.60 (1.10–5.46) –
TUMR on EC50 4.82 (2.15–7.49) – 4.72 (2.32–8.70) –
Residual variability, % 14.3 (14.1–14.5) – 14.2 (12.4–15.8) –
Safety endpoints
Platelets
BASE, 109/L 297 (287–307) 34.4 (32.1–36.4) 297 (285–308) 34.2 (32.2–36.6)
MTT, h 88.4 (84.2–92.6) 22.1 (19.7–24.3) 88.1 (66.4–107) 21.9 (16.6–35.9)
Emax 0.154 (0.135–0.173) 26.6 (20.1–31.8) 0.156 (0.103–0.304) 26.8 (16.4–34.6)
EC50, ng/mL 65.0 (60.0–70.0) 21.1 (18.0–23.8) 66.0 (55.1–110) 21.2 (16.7–25.4)
POW 0.0895 (0.0861–0.0929) – 0.0898 (0.0638–0.117) –
LAM 3.09 (2.82–3.36) – 3.01 (2.13–3.98) –
BWT on BASE -0.00327 (-0.00473 to -0.00181) – -0.00326 (-0.0045 to -0.00153) –
RAC on BASE -0.255 (-0.321 to -0.189) – -0.253 (-0.315 to -0.197) –
BEC on MTT 0.118 (0.0474–0.189) – 0.118 (0.0495–0.244) –
RAC on MTT -0.195 (-0.249 to -0.141) – -0.189 (-0.260 to -0.0921) –
BWT on Emax -0.00742 (-0.00935 to -0.00549) – -0.00752 (-0.00962 to -0.00553) –
TUMR on EC50 -0.108 (-0.155 to -0.0606) – -0.104 (-0.160 to -0.0548) –
Residual variability, % 24.0 (23.9–24.1) – 24.0 (22.8–25.2) –
ANC
BASE, 109/L 4.61 (4.42–4.80) 30.6 (28.5–32.7) 4.62 (4.43–4.82) 30.5 (28.1–32.7)
MTT, h 182 (177–187) 16.3 (13.8–18.4) 183 (172–192) 15.9 (12.8–20.3)
Emax 0.126 (0.118–0.134) 17.3 (13.7–20.3) 0.127 (0.108–0.211) 17.3 (11.8–21.3)
EC50, ng/mL 11.1 (9.42–12.8) 84.3 (75.0–92.7) 11.8 (6.61–25.9) 82.6 (48.8–120)
POW 0.152 (0.145–0.159) – 0.151 (0.129–0.180) –
LAM 1.72 (1.41–2.03) – 1.74 (0.679–3.25) –
BEC on BASE 0.134 (0.070–0.198) – 0.136 (0.0680–0.192) –
RAC on BASE -0.297 (-0.351 to -0.243) – -0.294 (-0.350 to -0.236) –
Residual variability, % 28.9 (28.7–29.1) – 28.9 (27.8–30.1) –
AST
BASE, U/L 21.5 (20.7–22.3) 31.8 (30.2–33.3) 21.6 (20.6–22.5) 31.9 (28.7–35.1)
Kout, h
-1 0.0142 (0.0114–0.0170) 120 (105–133) 0.0139 (0.0108–0.0161) 121 (94.9–141)
KPD, mL/ng 0.00572 (0.00536–0.00608) 33.8 (31.0–36.3) 0.00557 (0.00498–0.00600) 40.8 (31.4–49.6)
TUMR on BASE 0.117 (0.0564–0.178) – 0.100 (0.0284–0.175) –
BEC on KPD 0.200 (0.0928–0.307) – 0.211 (0.0813–0.367) –
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31.0 % (21.9–40.5), respectively. The differences between
these two schedules in predicted efficacy outcomes in
patients with advanced RCC were not considered clinically
relevant. Similar predictions were obtained for GIST
patients, such that the decrease in SLD and TTP slightly
favored Schedule 2/1, although differences in these out-
comes were not clinically relevant. No difference in ORR
was observed between schedules in GIST patients (see the
Results section and Fig. S4 of the ESM).
3.4.3 Safety Endpoints
Based on the final PK/PD safety models, trial simula-
tions were performed for each of the endpoints to assess
whether the predicted differences between the PK pro-
files of the two schedules had any impact on the selected
safety endpoints in patients with advanced RCC. The
simulation results indicated that the overall effect of
sunitinib on the selected safety endpoints was similar
Table 3 continued
Model results Bootstrap results
Estimate (95 % CI)a Intersubject
variability
(95 % CI)a
Estimate (95 % CI)a Intersubject
variability
(95 % CI)a
TUMR on KPD -0.175 (-0.256 to -0.0941) – -0.121 (-0.231 to 0.00935) –
Residual variability, % 25.7 (25.6, 25.8) – 26.0 (24.9–27.3) –
ALT
BASE, U/L 21.2 (20.5–21.9) 40.5 (38.2–42.7) 21.2 (20.5–22.1) 40.2 (37.4–43.6)
Kout, h
-1 0.00916 (0.00667–0.0116) 128 (102–150) 0.00937 (0.00676–0.0126) 126 (72.2–175)
KPD, mL/ng 0.00401 (0.00362–0.00440) 57.0 (52.3–61.3) 0.00400 (0.00347–0.00449) 57.2 (41.8–71.6)
BWT on BASE 0.376 (0.238–0.514) – 0.375 (0.226–0.498) –
Residual variability, % 37.3 (37.1–37.5) – 37.3 (35.1–39.2) –
Lymphocyte count
BASE, 109/L 1.51 (1.44–1.58) 40.2 (38.2–42.2) 1.50 (1.46–1.56) 40.2 (37.4–43.4)
MTT, h 243 (226–260) 28.2 (23.7–32.0) 247 (223–265) 26.8 (14.8–40.0)
KPD, mL/ng 0.000687 (0.000603–0.000771) 65.6 (56.7–73.3) 0.000677 (0.000523–0.000817) 70.5 (53.2–87.3)
POW 0.200 (0.183–0.217) – 0.211 (0.138–0.286) –
BEC on BASE -0.121 (-0.180 to -0.0620) – -0.121 (-0.192 to -0.0523) –
RAC on MTT –0.398 (–0.457 to -0.339) – -0.417 (-0.572 to -0.154) –
SCH on KPD -0.417 (-0.555 to -279) – -0.371 (-0.616 to -0.132) –
Residual variability, % 25.4 (25.2–25.6) – 25.4 (24.6–26.2) –
Left ventricular ejection fraction
BASE, % 62.2 (61.2–63.2) 8.61 (7.49–9.60) 61.9 (60.7–62.9) 8.53 (7.46–9.37)
Kout, h
-1 0.000656 (0.000409–0.000903) 82.8 (0.0–119) 0.000458 (0.0000783–0.0147) 128 (57.7–266)
KPD, mL/ng 0.00131 (0.000965–0.00165) 90.1 (67.3–108) 0.00139 (0.000649–0.0026) 104 (59.4–149)
RAC on BASE 0.0891 (0.0568–0.121) – 0.0852 (0.0598–0.107) –
SEX on BASE 0.0421 (0.0184–0.0658) – 0.0454 (0.0195–0.0681) –
Residual variability, % 7.89 (7.74–8.04) – 8.27 (7.39–8.99) –
Diastolic blood pressure
BASE, mmHg 74.6 (74.0–75.2) 9.38 (8.77–10.0) 74.5 (73.8–75.2) 9.36 (8.62–10.0)
Kout, h
-1 0.0288 (0.0149–0.0427) 108 (52.7–143) 0.0290 (0.0140–0.0508) 106 (37.4–181)
KPD, mL/ng 0.00184 (0.00169–0.00199) 47.6 (39.0–54.9) 0.00185 (0.00169–0.00207) 47.7 (38.5–55.3)
BWT on BASE 0.0691 (0.0383–0.0999) – 0.0707 (0.0373–0.104) –
Residual variability, % 10.4 (10.3–10.5) – 10.4 (10.0–10.7) –
ALT alanine aminotransferase, ANC absolute neutrophil count, AST aspartate aminotransferase, BASE baseline, BEC baseline Eastern Coop-
erative Oncology Group performance status, BWT baseline weight, CI confidence interval, EC50 drug concentration achieving 50 % of the
maximum effect, Emax maximum drug effect, Kout output elimination rate constant, KPD first-order rate constant, Ktol tolerance function, LAM
power function for the sigmoidal Emax model, MTT mean transit time from the proliferation compartment to the circulation compartment, PD
pharmacodynamic, PK pharmacokinetic, POW power function for the rebound feedback loop, RAC race, SCH dosing schedule, SE standard
error, TUMR tumor
a 95 % CI was estimated as (mean - 1.96 9 SE - mean ? 1.96 9 SE)
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between Schedules 4/2 and 2/1, with the exception of
PC, for which Schedule 2/1 was associated with a sig-
nificantly lower incidence of grades 3 and 4 thrombo-
cytopenic events than Schedule 4/2 (9 vs. 16 %; Fig. 7b–
h). Additionally, median (95 % CI) PC nadir values
during cycle 3 were significantly higher for Schedule 2/1
compared with Schedule 4/2 (119 [112–128] vs. 104
[94–114] 9 103/lL), further supporting the predicted
lower incidence rate of grades 3 and 4 thrombocytopenic
events for Schedule 2/1 in patients with advanced RCC
(Fig. 7b). Similar predictions were obtained for GIST
patients (see the Results section and Fig. S4 of the
ESM).
4 Discussion
In this analysis, PK/PD models predicting the effects of
sunitinib on the efficacy endpoint SLD and on several
safety endpoints were generated. The models predicted
that, in patients with advanced RCC or GIST, sunitinib
Schedule 2/1 dosing would have the same efficacy as
Schedule 4/2, despite some differences in the PK profiles of
the two schedules. The models also predicted that, in both
indications, sunitinib-related thrombocytopenia would be
less severe on Schedule 2/1 versus Schedule 4/2. The
findings from our study are supported by several retro-

















































Ktol (for SLD only)
B
A
Fig. 5 Schematics of the (a) mechanism-based PK/PD model, an
indirect response model, and (b) semi-mechanistic PK/PD model with
transit compartments in series plus a rebound feedback loop. Cc drug
concentration in the central compartment, Cp drug concentration in
the peripheral compartment, Circ effect concentration in the circu-
lation compartment, Edrug drug effect calculated using a basic or
sigmoidal maximum effect model, cf feedback loop power function,
Ka drug absorption rate constant, Ke drug elimination rate constant,
Kin input rate constant, Kout output (elimination) rate constant, Kcirc
elimination rate constant of the endpoint from the circulation
compartment, Kprol proliferation rate constant of the endpoint in the
proliferation compartment (e.g. stem cells), Ktol tolerance function,
Ktr transit rate constant, K12 drug distribution rate constant from
central to peripheral compartment, K21 drug redistribution rate
constant from peripheral to central compartment, PD pharmacody-
namic, PK pharmacokinetic, Prol effect concentration in proliferation
compartment, SLD sum of the largest diameter, Vc drug central
compartment volume of distribution, Vp drug peripheral compartment
volume of distribution
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27]. In addition, a prospective phase II trial of sunitinib
Schedule 4/2 versus Schedule 2/1 as first-line therapy in
metastatic RCC is ongoing (NCT02398552) and, once
completed, could support the findings of the PK/PD
modeling.
However, one of the limitations of these types of PK/PD
models was that they required continuous safety measures/
endpoints; therefore, categorical safety endpoints, such as
hand–foot syndrome, fatigue, nausea, vomiting, or diar-
rhea, could not be included in the PK/PD modeling anal-
yses. In addition, considering the similarities in the dose,
total dose, the average and steady-state plasma exposures
over any cycle (i.e. 6-week period) between the two dosing
schedules, the empirical models such as time to event
models or Markov-type models, would not be able to dif-
ferentiate between the two dosing schedules and hence
could not be utilized with respect to these categorical
safety endpoints. That said, prospective clinical studies
have shown that other categorical AEs, including fatigue,
hand–foot syndrome, stomatitis, and dysgeusia, improved
by changing from Schedule 4/2 to Schedule 2/1 [11, 27].
Another limitation of the model was that efficacy was
evaluated in patients with advanced RCC using the target
tumor SLD rather than PFS or overall survival. However,
SLD has been shown to be a reliable predictor of outcome
in RCC patients receiving vascular endothelial growth
factor-targeted therapies [28, 29].
The models generated here were based on a clinical
dataset with few patients treated on sunitinib Schedule 2/1
or 2/2. Therefore, for the covariate analyses, with respect to
the effect of dosing schedule on different PK or PK/PD
parameters, intermittent Schedules 2/2, 2/1, and 4/2 were
grouped together and compared with CDD schedules.































































































































































































Concentrations (95% CI) during the last day of the on-drug period (ng/mL)
Fig. 6 Trial simulations predicted mean PK profiles and median
(95 % CI) PK parameters during (a, c) cycle 3, following weekly
trough PK assessments, and (b, d) the last day of the on-drug period,
following PK assessments every 3 h, for sunitinib and SU12662 in
patients with advanced RCC receiving sunitinib 50 mg/day on
Schedule 4/2 (4 weeks on followed by 2 weeks off treatment) or
Schedule 2/1 (2-weeks-on followed by 1-week-off treatment). CI
confidence interval, PK pharmacokinetic, RCC renal cell carcinoma
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Fig. 7 Trial simulations
predicted mean profiles and
median (95 % CI) values for
(a) efficacy, and (b–h) safety
endpoints in patients with
advanced RCC receiving
sunitinib 50 mg/day on
Schedule 4/2 (4-weeks-on
followed by 2-weeks-off
treatment) or Schedule 2/1 (2-
weeks-on followed by 1-week-
off treatment), with
corresponding predictions for
ORR and PFS and adverse event
incident rates, following
assessments made twice every
6 weeks. CI confidence interval,
G grade of AE intensity, ORR
objective response rate, PFS
progression-free survival, RCC
renal cell carcinoma
1266 R. Khosravan et al.
supported by the diagnostic plots, which indicated a lack of
consistent noticeable differences in key PK or PK/PD
parameters for Schedule 2/1 or 2/2 versus Schedule 4/2.
The advantage of NONMEM analysis is that it enables the
pooling of patients bearing different characteristics because
the covariates (tumor, sex, schedule, etc.) are integrated
into the model. The PK and PK/PD models were indeed
verified and validated by VPC using both the working and
validation datasets, bootstrapping techniques, and plotting
of predicted population values versus observed population
values. The PK/PD models used were mainly semi-mech-
anistic PK/PD models with TCSFL or mechanism-based
IDR models as described by Danhof et al. [30]. These
models offer the advantage of including target-site distri-
bution, target binding and activation, PD interactions,
transduction, and homeostatic feedback mechanisms.
PK parameter values for sunitinib and its metabolite
estimated by the models used in this study agree well with
values estimated by other PK models in the literature [31]
and those reported in clinical studies in healthy volunteers
[32]. Trough plasma concentrations of sunitinib of
approximately 50 ng/mL were predicted by the models for
the two schedules and are in broad agreement with mea-
sured trough plasma concentrations previously reported
[33, 34]. The higher CL/F and Vc/F values in GIST patients
compared with RCC patients is mostly likely due to the
lower bioavailability of sunitinib in GIST patients com-
pared with RCC patients. This lower bioavailability in
GIST could be caused by the fact that the site of disease in
GIST is potentially impacting the absorption of sunitinib
from the GI tract. The covariates identified for CL/F and
Vc/F in the sunitinib final PK model, as well as the
SU012662 final model, were plausible and relevant and
most have been previously reported by Houk et al. [31].
Similarly, the majority of the covariates identified for
key parameters in the final PK/PD models for different
endpoints appeared to be plausible and relevant. For
example, for the efficacy endpoint SLD, it is highly plau-
sible that patients with poor performance status (i.e. ECOG
PS C 1) will have a greater target tumor SLD at baseline.
Similarly, the fact that the EC50 for efficacy was higher in
patients on Schedule CDD versus the intermittent dosing
schedule was also consistent with the clinical data indi-
cating lower PFS and ORR in patients on Schedule CDD
compared with patients on Schedule 4/2 [8]. Furthermore,
the EC50 for efficacy (i.e. the SLD) was significantly higher
for GIST compared with RCC (i.e. 177 vs. 30.5 ng/mL),
consistent with a lower observed PFS and ORR in GIST
compared with RCC following sunitinib therapy.
Although the intersubject variability in PK was low to
moderate, there was a large degree of intersubject vari-
ability associated with the EC50 for efficacy, as well as the
safety endpoints, indicating that establishing a universal
therapeutic window or target plasma concentration for
therapeutic drug monitoring purposes would not be feasi-
ble. Therefore, the curent approach to start patients with the
50 mg dose and then allow for dose adjustments (i.e.
incremental dose increase or decrease) based on individual
patient safety tolerability appears to be an appropriate and
practical approach and ensures that every patient achieves
optimal plasma exposures.
Our model predicted that sunitinib, regardless of sched-
ule, reduced target lesion SLD. Likewise, sunitinib was
predicted to induce neutropenia, a small reduction in LVEF,
lymphocytopenia, and fluctuating ALT, AST, and DBP, all
known AEs associated with sunitinib [2, 6, 16]. In a pivotal
trial comparing sunitinib versus interferon-a as first-line
treatment in patients with advanced RCC, sunitinib was
administered on Schedule 4/2 [6]; however, due to drug
toxicity, more than 35 % of patients in this trial underwent
dose interruptions, and more than 30 % had dose reductions.
Subsequently, research efforts have been undertaken to
identify optimal dosage schedules, and a number of retro-
spective reports regarding the efficacy and safety of
Schedule 2/1 in RCC have been published. For example,
Miyake et al. [27] and Najjar et al. [14] showed that, in RCC
patients switched from Schedule 4/2 to Schedule 2/1, the
incidence of AEs decreased after the switch. In both studies,
sunitinib-induced thrombocytopenia-related AEs of grade 3
or higher were experienced in a significantly smaller pro-
portion of patients on Schedule 2/1 than Schedule 4/2 [14,
27]. Grade 3 or higher AEs related to leukopenia and
hypertension associated with sunitinib treatment, were
experienced by a similar number of patients administered at
either of the two schedules [27]. In the study of Najjar et al.
[14], leukopenia-related AEs were experienced by fewer
sunitinib-treated patients on Schedule 2/1, but this difference
did not reach statistical significance. Two other retrospective
studies reported no loss of efficacy with sunitinib in patients
switched from Schedule 4/2 to Schedule 2/1 due to AEs [11,
12]; however, given the design of these studies, their results
must be interpreted with caution. In another retrospective
comparison of the two sunitinib schedules, Kondo et al. [13]
observed that, with Schedule 2/1, fewer patients required
dose interruptions due to AEs, and ORR and PFS were
similar between the two schedules. In that same study, fewer
patients experienced thrombocytopenia-related AEs of grade
3 or higher when on Schedule 2/1, but this was not statis-
tically significant.
5 Conclusions
Good agreement was observed between our model pre-
dictions and reported clinical data in patients with
advanced RCC treated with sunitinib on Schedule 4/2 or
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2/1. Similar findings were also observed in patients with
GIST, although clinical data for Schedule 2/1 in GIST are
lacking. Sunitinib Schedule 2/1 dosing offers a potential
alternative to Schedule 4/2 as it allows for management of
toxicity without loss of efficacy.
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